146 related articles for article (PubMed ID: 21792065)
1. Disease-modifying therapeutic concepts for HIV in the era of highly active antiretroviral therapy.
Butler SL; Valdez H; Westby M; Perros M; June CH; Jacobson JM; Levy Y; Cooper DA; Douek D; Lederman MM; Tebas P
J Acquir Immune Defic Syndr; 2011 Nov; 58(3):297-303. PubMed ID: 21792065
[TBL] [Abstract][Full Text] [Related]
2. Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection.
Hsu DC; Sereti I
Drugs; 2016 Apr; 76(5):533-49. PubMed ID: 26915027
[TBL] [Abstract][Full Text] [Related]
3. Structured treatment interruptions in HIV/AIDS therapy.
Lisziewicz J; Lori F
Microbes Infect; 2002 Feb; 4(2):207-14. PubMed ID: 11880054
[TBL] [Abstract][Full Text] [Related]
4. Structured treatment interruptions for the management of HIV infection.
Lori F; Lisziewicz J
JAMA; 2001 Dec; 286(23):2981-7. PubMed ID: 11743839
[TBL] [Abstract][Full Text] [Related]
5. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
[TBL] [Abstract][Full Text] [Related]
6. STI and beyond: the prospects of boosting anti-HIV immune responses.
Allen TM; Kelleher AD; Zaunders J; Walker BD
Trends Immunol; 2002 Sep; 23(9):456-60. PubMed ID: 12200068
[TBL] [Abstract][Full Text] [Related]
7. Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution.
Arici C; Ripamonti D; Ravasio V; Maggiolo F; Rizzi M; Finazzi MG; Suter F
Int J STD AIDS; 2001 Sep; 12(9):573-81. PubMed ID: 11516366
[TBL] [Abstract][Full Text] [Related]
8. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection.
Bekker V; Scherpbier H; Pajkrt D; Jurriaans S; Zaaijer H; Kuijpers TW
Pediatrics; 2006 Aug; 118(2):e315-22. PubMed ID: 16847077
[TBL] [Abstract][Full Text] [Related]
9. Immunologic function and virologic suppression among children with perinatally acquired HIV Infection on highly active antiretroviral therapy.
Rutstein RM; Gebo KA; Flynn PM; Fleishman JA; Sharp VL; Siberry GK; Spector SA
Med Care; 2005 Sep; 43(9 Suppl):III15-22. PubMed ID: 16116305
[TBL] [Abstract][Full Text] [Related]
10. Potential role of immune modulation in the effective long-term control of HIV-1 infection.
Rizzardi GP; Lazzarin A; Pantaleo G
J Biol Regul Homeost Agents; 2002; 16(1):83-90. PubMed ID: 12003181
[TBL] [Abstract][Full Text] [Related]
11. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
12. Is weak CD4+ gain in the course of suppressive combination antiretroviral therapy for HIV infection a current clinical challenge? A case report and brief review of the literature.
Tincati C; Merlini E; d'Arminio Monforte A; Marchetti G
BMC Infect Dis; 2018 Jan; 18(1):8. PubMed ID: 29304776
[TBL] [Abstract][Full Text] [Related]
13. Optimal timing and best antiretroviral regimen in treatment-naive HIV-infected individuals with advanced disease.
Manzardo C; Zaccarelli M; Agüero F; Antinori A; Miró JM
J Acquir Immune Defic Syndr; 2007 Sep; 46 Suppl 1():S9-18. PubMed ID: 17713424
[TBL] [Abstract][Full Text] [Related]
14. Short Intracellular HIV-1 Transcripts as Biomarkers of Residual Immune Activation in Patients on Antiretroviral Therapy.
Ishizaka A; Sato H; Nakamura H; Koga M; Kikuchi T; Hosoya N; Koibuchi T; Nomoto A; Kawana-Tachikawa A; Mizutani T
J Virol; 2016 Jun; 90(12):5665-5676. PubMed ID: 27030274
[TBL] [Abstract][Full Text] [Related]
15. Can Probiotics Reduce Inflammation and Enhance Gut Immune Health in People Living with HIV: Study Designs for the Probiotic Visbiome for Inflammation and Translocation (PROOV IT) Pilot Trials.
Kim CJ; Walmsley SL; Raboud JM; Kovacs C; Coburn B; Rousseau R; Reinhard R; Rosenes R; Kaul R
HIV Clin Trials; 2016 Jul; 17(4):147-57. PubMed ID: 27267710
[TBL] [Abstract][Full Text] [Related]
16. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial.
Maggiolo F; Ripamonti D; Gregis G; Quinzan G; Callegaro A; Suter F
AIDS; 2004 Feb; 18(3):439-46. PubMed ID: 15090796
[TBL] [Abstract][Full Text] [Related]
17. HIV disease and advanced age: an increasing therapeutic challenge.
Manfredi R
Drugs Aging; 2002; 19(9):647-69. PubMed ID: 12381235
[TBL] [Abstract][Full Text] [Related]
18. Persisting inflammation and chronic immune activation but intact cognitive function in HIV-infected patients after long-term treatment with combination antiretroviral therapy.
Pedersen KK; Pedersen M; Gaardbo JC; Ronit A; Hartling HJ; Bruunsgaard H; Gerstoft J; Ullum H; Nielsen SD
J Acquir Immune Defic Syndr; 2013 Jul; 63(3):272-9. PubMed ID: 23392469
[TBL] [Abstract][Full Text] [Related]
19. Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection: A Randomized Trial.
Lévy Y; Lelièvre JD; Assoumou L; Aznar E; Pulido F; Tambussi G; Crespo M; Meybeck A; Molina JM; Delaugerre C; Izopet J; Peytavin G; Cardon F; Diallo A; Lancar R; Béniguel L; Costagliola D
Ann Intern Med; 2020 Mar; 172(5):297-305. PubMed ID: 32040959
[TBL] [Abstract][Full Text] [Related]
20. Immune activation in the course of HIV-1 infection: Causes, phenotypes and persistence under therapy.
Younas M; Psomas C; Reynes J; Corbeau P
HIV Med; 2016 Feb; 17(2):89-105. PubMed ID: 26452565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
